SCHEMBL401117

SCHEMBL401117

CN(C)c1nc(N)nc2nc[nH]c12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 2/20 0.59
GDA Q9Y2T3 1/20 0.59
CDK2 P24941 12/20 0.56
CHEK1 O14757 1/20 0.56
AURKA O14965 1/20 0.56
CHEK2 O96017 1/20 0.56
HSP90AA1 P07900 1/20 0.56
HSP90AB1 P08238 1/20 0.56
PRKACA P17612 1/20 0.56
CCNE1 P24864 1/20 0.56
MARK3 P27448 1/20 0.56
RPS6KA3 P51812 1/20 0.56
PRKCD Q05655 1/20 0.56
LRRK2 Q5S007 1/20 0.56
MARK2 Q7KZI7 1/20 0.56
DPP4 P27487 1/20 0.56
MAP3K5 Q99683 1/20 0.56
CDK1 P06493 11/20 0.51
CCNB1 P14635 11/20 0.51
CCNA2 P20248 10/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL887836 0.84 DPP4 (0.44) PDPK1GDACDK2CHEK1AURKA
SCHEMBL7905650 0.80 EGFR (0.63) PDPK1GDACDK2DPP4MAP3K5
SCHEMBL6747380 0.79 CHEK1 (0.56) PDPK1CDK2CHEK1AURKACHEK2
SCHEMBL9705707 0.79 CDK2 (0.56) PDPK1GDACDK2CHEK1AURKA
Hydrochloric Acid SCHEMBL28922146 0.78 CDK2 (0.49) PDPK1GDACDK2DPP4MAP3K5
SCHEMBL28004524 0.78 EGFR (0.47) PDPK1GDACDK2DPP4MAP3K5
SCHEMBL10580001 0.76 PDPK1 (0.61) PDPK1GDACDK2DPP4MAP3K5
SCHEMBL28004918 0.76 PDPK1 (0.44) PDPK1GDACDK2DPP4MAP3K5
2,6-Diaminopurine SCHEMBL29143272 0.76 PDPK1 (0.92) PDPK1GDACDK2LRRK2DPP4
SCHEMBL320850 0.76 PDPK1 (0.66) PDPK1GDACDK2DPP4MAP3K5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4592399-B1 COMPOSITIONS, KITS AND METHODS FOR ISOLATING TARGET POLYNUCLEOTIDES DNAE DIAGNOSTICS LTD (GB) 2026-03-11 EP claimed
EP-4592399-A2 COMPOSITIONS, KITS AND METHODS FOR ISOLATING TARGET POLYNUCLEOTIDES DNAe Diagnostics Limited (GB) 2025-07-30 EP claimed
EP-4090768-B1 COMPOSITIONS, KITS AND METHODS FOR ISOLATING TARGET POLYNUCLEOTIDES DNAE DIAGNOSTICS LTD (GB) 2024-03-13 EP claimed
EP-4090768-A1 COMPOSITIONS, KITS AND METHODS FOR ISOLATING TARGET POLYNUCLEOTIDES DNAe Diagnostics Limited (GB) 2022-11-23 EP claimed
CN-115349019-A Compositions, kits and methods for isolating target polynucleotides DNAE诊断有限公司 2022-11-15 CN claimed
WO-2021144587-A1 COMPOSITIONS, KITS AND METHODS FOR ISOLATING TARGET POLYNUCLEOTIDES DNAE DIAGNOSTICS LIMITED (GB) 2021-07-22 WO claimed
US-10851407-B2 Left-handed gamma-peptide nucleic acids, methods of synthesis and uses therefor CARNEGIE MELLON UNIVERSITY (US) 2020-12-01 US claimed
EP-2873731-B1 NUCLEIC ACID PROBE, METHOD FOR DESIGNING NUCLEIC ACID PROBE, AND METHOD FOR DETECTING TARGET SEQUENCE DNAFORM KK (JP) 2018-08-29 EP claimed
US-20170058325-A1 Left-Handed Gamma-Peptide Nucleic Acids, Methods of Synthesis and Uses Therefor CARNEGIE MELLON UNIVERSITY 2017-03-02 US claimed
WO-2015172058-A1 LEFT-HANDED GAMMA-PEPTIDE NUCLEIC ACIDS, METHODS OF SYNTHESIS AND USES THEREFOR CARNEGIE MELLON UNIVERSITY (US) 2015-11-12 WO claimed
EP-2223931-A1 Novel nucleic acid base pair Japan Science and Technology Agency (JP) 2010-09-01 EP claimed
EP-2221311-A1 Novel nucleic acid base pair Japan Science and Technology Agency (JP) 2010-08-25 EP claimed
US-20090286247-A1 Novel nucleic acid base pair JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2009-11-19 US claimed
US-7374882-B2 Method for base sequencing and biologically active nucleic acids RIKEN (JP) 2008-05-20 US claimed
US-20050191689-A1 Novel nucleic acid base pair HIRAO, ICHIRO (JP) 2005-09-01 US claimed
US-20040115665-A1 Method for base sequencing and biologically active nucleic acids RIKEN (JP) 2004-06-17 US claimed
JP-2004514440-A 2004-05-20 JP claimed
EP-1348035-A2 METHOD FOR BASE SEQUENCING AND BIOLOGICALLY ACTIVE NUCLEIC ACIDS Riken (JP) 2003-10-01 EP claimed
WO-2002044195-A2 METHOD FOR BASE SEQUENCING AND BIOLOGICALLY ACTIVE NUCLEIC ACIDS RIKEN (JP) 2002-06-06 WO claimed
EP-1114827-A1 NOVEL NUCLEIC ACID BASE PAIR Japan Science and Technology Corporation (JP) 2001-07-11 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286247-A1 Novel nucleic acid base pair SNRPE, NSUN2, NSUN3 PDPK1 3801/4885GDA 406/4885CDK2 2222/4885
US-10851407-B2 Left-handed gamma-peptide nucleic acids, methods of synthesis and uses therefor NPPA, POLL, POLI PDPK1 3162/4885GDA 36/4885CDK2 4373/4885
US-20050191689-A1 Novel nucleic acid base pair SNRPE, NSUN2, NSUN3 PDPK1 3801/4885GDA 406/4885CDK2 2222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.